

1 **Wogonin attenuates nasal polyp formation by inducing eosinophil apoptosis through**
2 **HIF-1 α and survivin suppression**

3

4 Roza Khalмурatova, MD, PhD,¹ Mingyu Lee, BSc,^{1,2,6} Ji-Hun Mo, MD, PhD,^{3,8} YunJae Jung,
5 MD, PhD,^{4,9} Jong-Wan Park, MD, PhD,^{1,2,5,6} Hyun-Woo Shin, MD, PhD^{1,2,5,6,7,8*}

6

7 **Online Repository Methods**

8

9 **Immunofluorescence and confocal microscopy**

10 For double-immunofluorescence staining, 4- μ m tissue sections were deparaffinized in Neo-Clear
11 (Merck KGaA, Darmstadt, Germany) and rehydrated using a series of ethanol washes. Epitope retrieval
12 was performed by heating deparaffinized tissue sections in citrate buffer (10 mM sodium citrate, pH
13 6.0, 0.05% Tween 20) for 20 minutes at 98°C and cooling down in the same buffer for 20 minutes. After
14 this and each subsequent immunostaining step, the sections were washed 3 times, 5 minutes each, in 1 \times
15 PBS. Briefly, tissue sections were preincubated with PBS containing 0.1% Triton X-100 and 3% bovine
16 serum albumin (BSA), the corresponding rabbit-anti-HIF-1 α antibody (1:100; Novus Biologicals,
17 Littleton, CO), rabbit-anti-survivin antibody (1:200; Novus Biologicals) and mouse anti-EMBP
18 antibody (1:100; Santa Cruz Biotechnology) were applied and left overnight at 4°C. Tissue sections
19 were then incubated in a mixture of Alexa -488 and Alexa-555 (1:300; Invitrogen) conjugated
20 secondary antibodies diluted in blocking buffer for 2 hours at room temperature. Nuclei were
21 counterstained with DAPI, 1 μ g/mL, Sigma). Slides were mounted with fluorescence-mounting
22 medium (Vectashield, Vector Labs, Burlingame, CA). Images were acquired with a Zeiss fluorescent
23 microscope using AxioVision software (Carl Zeiss, Thornwood, NY). The HIF-1 α immunoreactivity
24 was mainly found in the nuclei, whereas positive staining of anti-EMBP and survivin was generally
25 found in the cytoplasm.

26 For evaluation of the expression of EMBP, HIF-1 α , survivin, and caspase-3-positive cells, in each
27 case, two interval slides were selected and observed to evaluate immunopositive cells. The mean
28 percentage of positive cells was calculated as positive cells/total cells \times 100% in at least two areas using
29 the \times 40 or \times 100 objective lens. The immunostaining was not observed in control sections incubated
30 with normal serum instead of the primary antibodies (data not shown).

31

32 **Animal model and tissue preparation**

33 All animal experiments were approved by the Institutional Animal Care and Use Committee of
34 Seoul National University and performed under strict governmental and international guidelines on
35 animal experimentation. A total of 60 male BALB/c mice (4 weeks old, 20–25 g) were purchased from
36 Central Laboratory Animal (Seoul, Korea) and housed for 1 week before initiating experiments. These
37 animals were kept in a special pathogen-free biohazard containment facility maintained at 22–24°C and
38 50–60% humidity.

39 The experimental protocol was designed as described previously with some modifications (Fig 1,
40 A)¹. The mice were randomly categorized into one control (group A; $n = 12$) and three experimental
41 groups (B, C, and D; $n = 16$ each).

42 The mice in the experimental group were systemically sensitized with 25 μ g OVA (Grade V; Sigma)
43 dissolved in 300 mL 1 \times PBS in the presence of 2 mg aluminum hydroxide gel adjuvant by
44 intraperitoneal injection on Day 0 and Day 5. At seven days after the last immunization, mice were
45 challenged intranasally with 3% OVA in 40 μ L of 1 \times PBS daily for seven days. Intranasal instillation
46 was performed in the head-down position, with the mouse head kept down for 30 seconds after
47 instillation to prevent pulmonary provocation. Prolonged continuous inflammation was maintained in
48 the experimental groups by the subsequent nasal challenge of mice to 3% OVA three times weekly for
49 12 consecutive weeks. Next, 10 ng of SEB (List Biological Laboratories, Inc., Campbell, CA) diluted
50 in PBS were challenged immediately after the instillation of 3% OVA during the last 8 consecutive
51 weeks (Group B). Wogonin (0.1 mg/kg; Sigma) was administered intranasally three times per week

52 from day 49 through day 102 before OVA instillation in Group C. Group D was intraperitoneally
53 injected with dexamethasone (1 mg/kg/w). In the control group, PBS was applied for both systemic and
54 local stimulation. Mice were sacrificed 24 hours after the last intranasal administration. The sinonasal
55 specimens and nasal lavage were collected and processed according to the method previously described¹.
56 After partial tracheal resection, a micropipette was inserted into the choana through the tracheal opening
57 in the direction of the upper airway. Each nasal cavity was gently perfused with 200 μ L PBS and the
58 fluid from the nostril was collected and centrifuged. The supernatants were stored at -80°C prior to use.
59 Cell pellets were suspended in PBS and spun onto a slide. After the slides were dried, cells were fixed
60 and stained using Diff-Quik stain (Dade Behring, Marburg, Germany) according to manufacturer
61 instruction. The heads of mice from each group (n = 6 for control mice, n = 8 for OVA/SEB untreated
62 group, n = 8 for OVA/SEB-challenged group with intranasal administration of wogonin, n = 8
63 OVA/SEB-challenged group treated with dexamethasone) were removed *en bloc* and then fixed in 4%
64 paraformaldehyde for histopathologic analysis. After exposing the nasal cavities of the other mice, the
65 nasal mucosa was taken out meticulously with a small curette and microforceps under microscopic
66 vision.

67

68 **Histopathological analysis of animal tissues**

69 For evaluation of nasal histopathology, nasal tissues were decalcified, dehydrated, and processed
70 according to standard paraffin-embedding procedures. The tissues were cut in coronal sections at 4- μ m
71 thickness. An atlas of normal murine sinonasal anatomy was used to standardize the anatomic locations
72 being examined². Several stains were utilized to compare characteristics between groups: hematoxylin
73 and eosin (H&E) for polyp-like lesions, Sirius red for eosinophils, periodic acid-Schiff (PAS) stain for
74 goblet cells, and Masson trichrome stain to measure subepithelial and epithelial thicknesses. We chose
75 10 areas from nasal mucosal sections randomly for evaluation under hpf (magnification $\times 1000$) that
76 were measured by 2 examiners who were blind to group assignment. Polyp-like lesions were defined
77 as distinct mucosal elevations with eosinophilic infiltration and microcavity formation. Three
78 consecutive slides were reviewed to exclude processing errors. Mucosal thickness was measured as the

79 distance between the apex of the epithelial cells and the upper border of the subepithelial glands zone
80 by using an image analysis system. For assessment of mucosal thickness, at least 3 measurements at
81 random points with a minimum distance of 20- μ m between the points were made in the appropriate
82 area of each hpf, and the mean from 4 different hpfs was recorded for comparison.

83

84 **Immunohistochemical analysis**

85 Immunohistochemistry was performed by using the polink-2 plus polymerized horseradish
86 peroxidase (HRP) broad DAB Detection System (Golden Bridge International Labs., Mulkiteo, WA).
87 Paraffin sections of nasal tissue were mounted on slides and dried at room temperature for 24 hours.
88 The sections were deparaffinized, rehydrated, and autoclaved at 121°C for 10 minutes in 100 mmol/L
89 citrate buffer (pH 6.0; Dako, Glostrup, Denmark) to retrieve antigens. After treatment with 3%
90 hydrogen peroxide (Sigma) in methanol for 10 minutes, the sections were incubated in 3% BSA at room
91 temperature for 1 hour to block nonspecific signals. Tissue sections were incubated against survivin
92 (1:200), collagen type I (1:500, Abcam, Cambridge, MA) and neutrophil-elastase (1:200, Abcam)
93 overnight at 4°C. The sections were incubated in broad antibody enhancer and polymer-HRP and then
94 stained with the DAB Detection System. To standardize color development, the incubation time for
95 diaminobenzidine staining was fixed in all experiments. Sections were counterstained with Gill's
96 hematoxylin for 3 minutes and dehydrated through a graded ethanol series, cleared with xylene, and
97 coverslipped with mountant. Negative controls were performed by omitting the primary antibody.
98 Unless noted otherwise, all manufacturer instructions were followed. The slides were evaluated with a
99 bright-field microscope (BX-51; Olympus, Tokyo, Japan) and a micrograph field of view of the
100 entire stained section. The immunostaining was not observed in control sections incubated with normal
101 serum instead of the primary antibodies (data not shown).

102

103 **Detection of apoptotic cells with the TUNEL assay**

104 Apoptotic cells were visualized using the TUNEL technique (Novus). Fixed tissue sections were
105 deparaffinized, rehydrated, treated with proteinase K, and incubated with a terminal deoxynucleotidyl

106 transferase (TdT) enzyme solution at 37°C for 2 hours. The reaction was carried out at 37°C for
107 30 minutes and terminated in a stop and wash buffer provided by the supplier. The sections were
108 incubated with anti-digoxigenin peroxidase and then with diaminobenzidine containing 0.01% H₂O₂ for
109 5 minutes. Finally, the sections were lightly counterstained with H&E and examined under a microscope.
110 No staining was evident in negative controls when omitting the TdT enzyme. All of the procedures were
111 performed according to the manufacturer's instructions.

112

113 **Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) for** 114 **inflammatory markers, chemokines, and transcription factors**

115 Total RNA was isolated from the tissue samples (n = 6 for control mice, n = 8 for OVA/SEB
116 untreated group, n = 8 for OVA/SEB-challenged group with intranasal administration of wogonin, and
117 n = 8 for OVA/SEB-challenged group treated with dexamethasone) by using the RNeasy Plus Mini Kit
118 (Qiagen, Germany). Total RNA (1 µg) was reverse transcribed to cDNA using the Quantitect Reverse
119 Transcription Kit (Qiagen). Quantitative real-time PCR was performed using the Top real qPCR 2xPre
120 MIX (SYBR Green with low ROX) with primers that specifically amplify genes for eosinophil cationic
121 protein (ECP), IL-4, IL-13, IFN- γ , IL-17A, CXCL1, CXCL2, CCL11, CCL24, T-box transcription
122 factor (T-bet), GATA3, and RAR-related orphan receptor γ (ROR- γ). Expression of glyceraldehyde-3-
123 phosphate dehydrogenase (*Gapdh*) was used as an internal control for normalization (Table E1).
124 Cycling conditions were 95°C for 10 minutes, followed by 40 cycles at 95°C for 10 seconds, 50°C for
125 1 minute, and 72°C for 1 minute. Relative gene expression was calculated by using the comparative 2-
126 $\Delta\Delta C_q$ method. The PCR efficiency in all runs was close to 100%, and all samples were tested in
127 duplicate.

128

129 **Quantitative determination of OVA-specific and total IgE in serum and nasal lavage**

130 Blood was collected via cardiac puncture 24 hours after the last intranasal administration,
131 centrifuged, serum removed, and stored at -80°C. Quantitative assessments of OVA-specific IgE and

132 total IgE in serum and nasal lavage were performed using an enzyme-linked immunosorbent assay
133 (ELISA) kit purchased from BioLegend (San Diego, CA). The sensitivity of OVA-specific IgE and total
134 IgE was 20.7 pg/mL and 0.1 ng/mL, respectively. All procedures were performed according to
135 manufacturer instruction.
136

137 **References**

138 E1. Kim, D. W. *et al.* Staphylococcus aureus enterotoxin B contributes to induction of nasal
139 polypoid lesions in an allergic rhinosinusitis murine model. *Am J Rhinol Allergy* **25**, e255-261 (2011).

140 E2. Jacob, A. & Chole, R. A. Survey anatomy of the paranasal sinuses in the normal mouse.
141 *Laryngoscope* **116**, 558-563 (2006).

142

143 **Online Repository Figure Legends**

144

145 **Fig E1.** Representative western blots of cleaved caspase-3 and PARP in EoL-1, THP-1, and RPMI 2650
146 cells after YC-1 and chaetocin treatment. **A.-C.** Representative western blots of cleaved caspase-3 and
147 PARP in EoL-1, THP-1, and RPMI 2650 cells treated with YC-1 and chaetocin incubated under
148 normoxic and hypoxic conditions for 24 hours (h).

149

150 **Fig E2.** Representative western blots of cleaved caspase-3 in EoL-1, THP-1, RPMI 2650, and THP-1
151 cells after wogonin treatment. **A.-D.** Representative western blots of cleaved caspase-3 in EoL-1, THP-
152 1, RPMI 2650, and HMC-1 cells treated with wogonin and incubated under normoxic and hypoxic
153 conditions for 16 and 24 hours.

154

155 **Fig E3.** Immunohistochemical observations of survivin expression. **A.** Immunochemical staining of
156 survivin was performed in nasal mucosal tissue from control subjects and patients with CRSsNP, a
157 patient with CRSwNP, and an NP sample. A high number of survivin-positive immune cells was
158 detected in NP tissue (original magnification $\times 1000$). **B.** The percentage of survivin-positive immune
159 cells was significantly greater in the NP tissues. The black box indicates the magnified area. Data are
160 expressed as the means \pm SD. $*P < 0.05$, $**P < 0.01$. Mann-Whitney *U* test. Scale bar = 50 μ m.

161

162 **Fig E4.** Photographs of representative epithelial disruptions and neutrophil elastase-positive cells in
163 mice. **A., B.** The numbers of epithelial disruptions were reduced in Groups C and D compared with that
164 in Group B (Hematoxylin and eosin; original magnification $\times 400$). **C.** Representative photographs and
165 **(D)** quantitative analysis of neutrophil elastase-positive cells (IHC; original magnification $\times 1000$). Data
166 are expressed as the means \pm SD. $*P < 0.05$, $**P < 0.01$. Mann-Whitney *U* test. Scale bar = 20 μ m.

167

168 **Fig E5.** Cytologic assessment of the nasal lavage and total and OVA-specific IgE production. **A.**
169 Microscopic examination of nasal lavage stained with the standard Diff-Quik protocol. Nasal cytology

170 shows a predominance of eosinophilic infiltration in Groups B, C, and D. Black arrows point to an
171 eosinophil with apoptotic morphology (original magnification, $\times 1000$, bright field) in Group C. **B., C.**
172 Percentage of apoptotic cells and total inflammatory cells count in each group. **D.-G.** The level of total
173 IgE and OVA-specific IgE from serum and nasal lavage measured by enzyme-linked immunosorbent
174 assay (ELISA). Data are expressed as the means \pm SD. $*P < 0.05$, $**P < 0.01$. Mann-Whitney *U* test.
175 Scale bar = 20 μm .

176

177 **Fig E6.** TUNEL and survivin-positive cells in a murine nasal polyp model. **A.** Representative
178 photographs of TUNEL and survivin-stained sections and **(B., C)** quantitative analysis of TUNEL and
179 survivin-positive cells (original magnification, $\times 1000$, bright field). Arrows denote TUNEL-positive
180 apoptotic cells in the wogonin-treated group. Data are expressed as the means \pm SD. $*P < 0.05$, $**P <$
181 0.01 . Mann-Whitney *U* test. Scale bar = 20 μm .

182

183 **Fig E7.** Histopathological evaluation of nasal mucosal tissue. **A.** Representative photographs of Sirius
184 red, Giemsa, periodic acid-Schiff (PAS), Masson' trichrome, and collagen type I (original magnification,
185 $\times 1000$)-stained nasal tissue sections. **B., C.** The presence of eosinophils and mast cells were detected
186 in Groups B, C, and D. Group B showed a markedly denser distribution of eosinophils than groups C
187 and D. **E.-G.** Comparison of epithelial, subepithelial thicknesses, and collagen type I among the groups.
188 Groups C and D showed less collagen deposition than Group B in sinonasal tissue sections. Data are
189 expressed as the means \pm SD. $*P < 0.05$, $**P < 0.01$. Mann-Whitney *U* test. Scale bar = 20 μm .

190

191 **Fig E8-12.** Uncropped Images of Immunoblots

192

193 **Fig E13.** Schematic illustration of the study.

194 **Table E1. qPCR primers used in this study.**

ECP :	F: 5'-TCGGAGTAGATTCCGGGTG-3' R: 5'-GAACCACAGGATACCGTGGAG-3'
IL-4:	F: 5'-AGATGGATGTGCCAAACGTCCTCA-3' R: 5'-AATATGCGAAGCACCTTGGAAGCC-3'
IL-13:	F: 5'-TGAGGAGCTGAGCAACATCACACA-3' R: 5'-TGCGGTTACAGAGGCCATGCAATA-3'
IFN-g:	F: 5'-TCCACATCTATGCCACTTGAG-3' R: 5'-CTGAGACAATGAACGCTACACA-3'
CXCL1:	F: 5'-GTGCCATCAGAGCAGTCT-3' R: 5'-CCAAACCGAAGTCATAGCCA-3'
CXCL2:	F: 5'-CTTCCAGGTCAGTTAGCCTT-3' R: 5'-CAGAAGTCATAGCCACTCTCAAG-3'
CCL11:	F: 5'-TGTAGCTCTTCAGTAGTGTGTTG-3' R: 5'-CTTCTATTCCCTGCTGCTCACG-3'
CCL24:	F: 5'-GTACAGATCTTATGGCCCTTCT-3' R: 5'-CTGCACGTCCTTTATTTCCAAG-3'
IL-17A:	F: 5'-CTCCAG AAGGCCCTCAGACTA-3' R: R: 5'-AGCTTTCCCTCCGCATTGACA-3'
T-bet:	F: 5'-CAAGACCACATCCACAAACATC-3' R: 5'-TTCAACCAGCACCAGACAG-3'
GATA3:	F: 5'-GAAGGCATC CAGACCCGAAAC-3' R: 5'-ACCCATGGCGGTGACCATGC-3'
ROR-g:	F: 5'-ACCTCTTTTCACGGGAGGA-3' R: 5'-TCCCACATCTCCCACATTG-3'
GAPDH:	F: 5'-TGCACCACCAACTGCTTAG-3' R: 5'-GGATGCAGGGATGATGTTC-3'

195

196

Figure E1




Figure E2




Figure E3




Figure E4





Figure E5



205

206

207

Figure E6





Figure E7




210

211

Figure E8

Fig 2A




212

213

Figure E9

Fig 3A



214

215

Figure E10




Figure E11






Figure E12



220

221

Figure E13



222

223